GSK's mepolizumab hits main goals in 2 asthma trials

03/13/2014 | Reuters

GlaxoSmithKline's asthma drug mepolizumab achieved the primary goals of two late-stage trials. In one of them, patients with severe eosinophilic asthma who took the drug showed a significant decrease in frequency of exacerbations compared with those on placebo. In the other trial, mepolizumab users showed a greater decrease in oral corticosteroid dosage while maintaining asthma control compared with placebo users. The firm plans to submit the drug for regulatory review worldwide by the end of this year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA